Literature DB >> 416483

[Experimental study on the therapeutic action of Ro 7-1051 on infections caused by different strains of Trypanosoma cruzi].

S G Andrade, R M Figueira.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 416483

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


× No keyword cloud information.
  5 in total

1.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Benznidazole therapy in Trypanosoma cruzi-infected mice blocks thymic involution and apoptosis of CD4+CD8+ double-positive thymocytes.

Authors:  B P Olivieri; D A Farias-De-Oliveira; T C Araujo-Jorge; V Cotta-de-Almeida
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.

Authors:  S G Andrade; J B Magalhães; A L Pontes
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

4.  Therapeutic action of MK-436 (2,5-nitroimidazole) on Trypanosoma cruzi infections in mice: a parasitological, serological, histopathological, and ultrastructural study.

Authors:  S G Andrade; R C Silva; C M Santiago; L A Freitas
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

Review 5.  Experimental and Clinical Treatment of Chagas Disease: A Review.

Authors:  Policarpo Ademar Sales Junior; Israel Molina; Silvane Maria Fonseca Murta; Adrián Sánchez-Montalvá; Fernando Salvador; Rodrigo Corrêa-Oliveira; Cláudia Martins Carneiro
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.